ArticleInternational journal of clinical and experimental pathology2019
The downregulation of miR-519a predicts poor prognosis and contributes to tumor progression in gastric cancer.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Three possible diagnostic biomarkers for gastric cancer: miR-362-3p, miR-362-5p and miR-363-5p.Biomarkers in medicine · 2024Article
- Underlying mechanisms and clinical potential of circRNAs in glioblastoma.Oncology research · 2023Review
- Review
- MicroRNA-891a-5p is a novel biomarker for non-small cell lung cancer and targets HOXA5 to regulate tumor cell biological function.Oncology letters · 2021Article
- CircNUP98 Suppresses the Maturation of miR-519a-3p in Glioblastoma.Frontiers in neurology · 2021Article
- miR-4636 inhibits tumor cell proliferation, migration and invasion, and serves as a candidate clinical biomarker for gastric cancer.Oncology letters · 2021Article
- MiR-1231 decrease the risk of cancer-related mortality in patients combined with non-small cell lung cancer and diabetes mellitus.Cancer cell international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMicroRNAs (miRNAs) have been demonstrated to be involved in the pathogenesis of various human cancers. However, the role of microRNA-519a (miR-519a) in gastric cancer (GC) remains unclear. This study aimed to investigate the clinical value and biological function of miR-519a in GC.
methodsThe expression of miR-519a in GC tissues and cell lines was estimated by quantitative real-time polymerase chain reaction (qRT-PCR). A survival analysis for GC patients was performed using the Kaplan-Meier method. A Cox regression analysis was used to confirm the prognostic value of miR-519a. The biological function and potential targets of miR-519a in GC progression were assessed using cell experiments.
resultsIn this study, we found that miR-519a was an important tumor suppressor with downregulated expression in GC tissues and cells compared with the normal controls (all
conclusionAll the data in the present study revealed that the downregulated expression of miR-519a predicts the poor prognosis of GC and is involved in the regulation of GC progression. We consider that miR-519a may be a candidate therapeutic target for GC treatment.
Indexed as
Identifiers
31934076PMC6949548What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.